Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 10/20 | 0.49 |
| ▸ | TNF | P01375 | 5/20 | 0.49 |
| ▸ | IL1B | P01584 | 3/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249736 | 1.00 | CRBN (0.49) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL29518016 | 1.00 | CRBN (0.49) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2250370 | 0.98 | CRBN (0.48) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL26317758 | 0.94 | CRBN (0.47) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL26321489 | 0.94 | CRBN (0.47) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2250493 | 0.94 | TNF (0.43) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2252482 | 0.93 | CRBN (0.44) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2249640 | 0.92 | TNF (0.51) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30493897 | 0.92 | TNF (0.51) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2255353 | 0.92 | CRBN (0.51) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007679-A1 | METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250032502-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | CELGENE CORPORATION (US) | 2025-01-30 | — | — | US | disclosed |
| US-12064437-B2 | Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies | CELGENE CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240041894-A1 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | CELGENE CORPORATION | 2024-02-08 | — | — | US | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3145513-B1 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | CELGENE CORP (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116234553-A | Methods of treating systemic lupus erythematosus and use of biomarkers as predictors of clinical sensitivity to therapy | 新基公司 | 2023-06-06 | — | — | CN | disclosed |
| US-11660302-B2 | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus | CELGENE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230159490-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2015085172-A2 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150038511-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | CELGENE CORPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20140343058-A1 | TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | CELGENE CORPORATION | 2014-11-20 | — | — | US | disclosed |
| US-20140045844-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | CELGENE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045843-A1 | METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041894-A1 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, BCL6B, BCL6 | CRBN 2916/4885IKZF3 975/4885TNF 2177/4885 |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | CRBN 2429/4885IKZF3 2341/4885TNF 4590/4885 |
| US-20140343058-A1 | TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, SGMS1, SGMS2 | CRBN 3933/4885IKZF3 965/4885TNF 561/4885 |
| US-20260007679-A1 | METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | MALT1, BCL6, BCL9 | CRBN 152/4885IKZF3 528/4885TNF 3112/4885 |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | CRBN 2429/4885IKZF3 2341/4885TNF 4590/4885 |
| US-11660302-B2 | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus | SSB, BCL6B, BCL6 | CRBN 2916/4885IKZF3 975/4885TNF 2177/4885 |
| US-20250032502-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | IKZF3, IRF2BP2, IRF3 | CRBN 2585/4885IKZF3 1/4885TNF 1116/4885 |
| US-20150038511-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | MYD88, CD14, NFATC1 | CRBN 1103/4885IKZF3 102/4885TNF 74/4885 |
| US-20140045844-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | MYD88, CD14, NFATC1 | CRBN 1103/4885IKZF3 102/4885TNF 74/4885 |
| US-20140045843-A1 | METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | VHL, TP53, BRCA1 | CRBN 1726/4885IKZF3 2975/4885TNF 4550/4885 |
| US-20230159490-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | MYD88, CD14, NFATC1 | CRBN 1103/4885IKZF3 102/4885TNF 74/4885 |
| US-12064437-B2 | Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies | IKZF3, IRF2BP2, IRF3 | CRBN 2585/4885IKZF3 1/4885TNF 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.